Abivax S.A. Abivax S.A.

Abivax S.A.

ABVX

Classifica tra le azioni #2416
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Prezzo delle azioni
$93.77
Capitalizzazione di mercato
$8.18B
Variazione (1 giorno)
-1.01%
Variazione (1 anno)
6.11%
Paese
FR
Scambia Abivax S.A. (ABVX)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per Abivax S.A. (ABVX)
L’azione Abivax S.A. (simbolo: ABVX) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Oct 22, 2026.
Una quota di ABVX acquistata prima di Oct 22, 2026 equivale oggi a 0 quote di ABVX.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
US
1 x3
AU
0 -
NL
1 x100
BE